胃/胃食管结合部腺癌新辅助治疗的现状及研究进展

The Current Status and Research Progress of Neoadjuvant Therapy for GC/EGJ

胃/胃食管结合部腺癌(GC/EGJ)在世界的癌症发病率中位居前五,严重威胁着人们的身体健康,患者确诊时往往已经是局部晚期。新辅助治疗(NAT)是一种全新的综合治疗模式,旨在提升患者的预后并减少GC/EGJ复发。新辅助化疗(NACT)已经得到临床证实,能够为患者带来良好的疗效,但不同方案的差异还需要进一步研究。免疫治疗、靶向治疗在晚期GC/EGJ患者中的应用已经十分出色,在NAT中的疗效还在进一步研究中,但初步结果已经足够令人惊喜。综述了GC/EGJ中应用新辅助治疗的现状及研究进展。

GC/EGJ ranks among the topfive cancers in the world in incidence rate,which seriously threatens people’s health,and patients are often locally advanced when diagnosed.Neoadjuvant therapy(NAT)is a novel comprehensive treatment approach aimed at improving patient prognosis and reducing GC/EGJ recurrence.Neoadjuvant chemotherapy(NACT)has been clinically proven to bring good therapeutic effects to patients,but the differences between different regimens still need further research.The application of immunotherapy and targeted therapy in advanced GC/EGJ patients has been excellent,and the efficacy in NAT is still under further research,but the preliminary results are already surprising enough.This article reviews the current status and research progress of neoadjuvant therapy in GC/EGJ.